

Article type: Original Research Article

Title: Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

Authors: Sherko Kuemmel^{1,2*}, Carlo A. Tondini³, Jacinta Abraham⁴, Zbigniew Nowecki⁵, Bartosz Itrych^{6,†}, Erika Hitre⁷, Bogusława Karaszewska⁸, Alejandro Juárez-Ramiro⁹, Flavia Morales-Vásquez¹⁰, Jose Manuel Pérez García^{11‡}, Servando Cardona-Huerta¹², Estefania Monturus¹³, Marco Sequi^{14,15§}, Eleonora Restuccia¹³, Mark Benyunes¹⁶ and Miguel Martín¹⁷

Author affiliations:

¹ Breast Unit, Kliniken Essen-Mitte, Essen, Germany

² Clinic for Gynecology with Breast Center, Charité – Universitätsmedizin Berlin, Berlin, Germany

³ Department of Onco-Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy

⁴ Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, UK

⁵ Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej, Centrum Onkologii-Instytut, Warsaw, Poland

⁶ Department of Oncology, Magodent, Warsaw, Poland

⁷ Department of Medical Oncology and Clinical Pharmacology “B”, National Institute of Oncology, Budapest, Hungary

⁸ Przychodnia Lekarska KOMED, Konin, Poland

⁹ Medical Oncology, CME Consultorio de Medicina Especializada, Mexico City, Mexico

¹⁰ FUCAM, Instituto Nacional de Cancerología de Mexico, Mexico City, Mexico

¹¹ Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain

¹² Centro de Cáncer de Mama, Hospital Zambrano-Hellion, Tecnológico de Monterrey, Monterrey, Mexico

¹³ Global Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland

¹⁴ Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland

¹⁵ Biostatistics, PAREXEL, Milan, Italy

¹⁶ Global Product Development, Genentech, Inc., South San Francisco, CA, USA

¹⁷ Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense de Madrid, Madrid, Spain

*** Corresponding author:** Sherko Kuemmel, MD, PhD

Address: Breast Unit, Kliniken Essen-Mitte, Henricistrasse 92, 45136 Essen, Germany

Telephone: +49-201-174-33001

Email: s.kuemmel@kem-med.com

† Current address: Department of Oncology and Hematology, Central Clinical Hospital MSWiA, Warsaw, Poland (Itrych)

‡ **Current address:** International Breast Cancer Center (IBCC), Quiron Group, Barcelona,
Spain (Pérez García)

§ Current address: CROS Academy, Bologna, Italy (Sequi)

Target journal: *Breast Cancer Research and Treatment*

Online Resource 3 – Treatments received following discontinuation of study treatment

	H SC + P IV + D IV (N = 412)
Patients with ≥ 1 treatment	195 (47.3)
Number of treatments	515
HER2-targeted therapies	160 (82.1)
Trastuzumab	83 (42.6)
Pertuzumab	30 (15.4)
Lapatinib	51 (26.1)
Ado-trastuzumab emtansine	77 (39.5)
Capecitabine	76 (39.0)
Vinorelbine	22 (11.3)
Taxanes	15 (7.7)

D IV intravenous docetaxel, *HER2* human epidermal growth factor receptor 2, *H SC* subcutaneous trastuzumab, *P IV* intravenous pertuzumab

Data are number of patients (%) who received subsequent treatment for breast cancer